Cyramza ® (ramucirumab) injection

10 mg/mL solution

The below information is provided in response to your request and may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above.

CYRAMZA® (ramucirumab): Indications for Use

Cyramza (ramucirumab) is indicated for the treatment of patients with gastric/GEJ adenocarcinoma, NSCLC and mCRC.

CYRAMZA® (ramucirumab): Indications for Use

Ramucirumab is a human VEGFR-2 antagonist indicated:

  • as a single agent or in combination with paclitaxel, for treatment of advanced gastric or GEJ adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.1

  • in combination with docetaxel, for treatment of metastatic NSCLC with disease progression on or after platinum-based chemotherapy.1

    • Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving ramucirumab.1

  • in combination with FOLFIRI, for the treatment of mCRC with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.1

Enclosed Prescribing Information

CYRAMZA® (ramucirumab) injection, for intravenous use, Lilly

Reference

1. Cyramza [package insert]. Indianapolis, IN: Eli Lilly and Company; 2017.

Glossary

ALK = anaplastic lymphoma kinase 

GEJ = gastroesophageal junction

EGFR = epidermal growth factor receptor

FDA = Food and Drug Administration 

FOLFIRI = irinotecan, folinic acid, and 5-fluorouracil

mCRC = metastatic colorectal cancer

NSCLC = non-small cell lung cancer

VEGFR-2 = vascular endothelial growth factor receptor 2

Date of Last Review: February 12, 2018

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 8pm ET

Or you can

Ask us a question Chat with us

Submit a question

Visit Us @LillyMedical